Bio-Thera Solutions Has China’s First Adalimumab Biosimilar
Qletli Is Only The Second Biosimilar Approved In China
Executive Summary
Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).
You may also be interested in...
Shanghai Junshi Announces Chinese Adalimumab Approval
Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.
Bio-Thera Conducts Simponi Phase III Trial
China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.
Pfizer Fails To Make Its Mark In China-Focused Biosimilars Market
Pfizer threw in the towel for biosimilar development in China last week, just three years after opening its $350m Global Biotechnology Center, based in the Hangzhou Economic Development Area.